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ABSTRACT
Taking advantage of eight established cell lines from colorectal cancer
patients at different stages of the disease and the fact that all of them
could form spheres, cell surface biomarkers of cancer stem cells
and epithelial-mesenchymal transition were tested. The aim was to
investigate cancer stem cells and metastatic stem cells in order to
provide functional characterization of circulating tumor cells and
promote the development of new anti-metastatic therapies. Our
model showed an important heterogeneity in EpCAM, CD133, CD44,
LGR5, CD26 and E-cadherin expression. We showed the presence of
a subset of E-cadherin+ (some cells being E-cadherinhigh) expressing
CD26+ (or CD26high) together with thewell-knownCSCmarkers LGR5
and EpCAMhigh, sometimes in the absence of CD44 or CD133. The
already described CD26+/E-cadherinlow or negative and CD26+/
EpCAM−/CD133− subsets were also present. Cell division drastically
affected the expression of all markers, in particular E-cadherin, so new-
born cells resembled mesenchymal cells in surface staining. CD26
and/or dipeptidyl peptidase 4 inhibitors have already shown anti-
metastatic effects in pre-clinical models, and the existence of these
CD26+ subsets may help further research against cancer metastasis.
KEY WORDS: Colorectal cancer, Cancer stem cells, Epithelial-
mesenchymal transition, Biomarkers, CD26, EpCAM, LGR5,
E-cadherin, CD133
INTRODUCTION
Metastasis accounts for the vast majority of deaths due to cancer
because even if the primary tumor has been perfectly removed by
surgery, tumor cells can have disseminated and established
themselves in distant locations (Oskarsson et al., 2014; Pantel
et al., 2008; Liu et al., 2014a,b; Miranda-Lorenzo et al., 2014;
Driessens et al., 2012). Cancer stem cells (CSCs) are the only tumor
cell type with long-term self-renewal potential because of their
microenvironmental niche (Oskarsson et al., 2014; Liu et al., 2014a,
b; Miranda-Lorenzo et al., 2014), suggesting that metastatic stem
cells (MetSCs) with tumor-initiating capacity already exist in the
primary tumor (Oskarsson et al., 2014; de Sousa e Melo et al.,
2017). Since metastasis does not rely on driver mutations, and
genomic biomarkers are not useful for diagnosis (Vanharanta and
Massagué, 2013), the possibility that MetSCs may be tracked is
especially important for metastasis diagnosis and development of
therapeutic approaches that kill them (Oskarsson et al., 2014).
Cell surface markers are powerful tools, for example, for isolating
distinct cell populations from freshly harvested primary tumors
(Miranda-Lorenzo et al., 2014) or blood. However, the expression
levels of markers of CSCs change depending on environmental
conditions; they are not reproducible across or even within similar
tumor types, and they are not exclusive of a functional CSC
phenotype (Miranda-Lorenzo et al., 2014; Driessens et al., 2012; de
Sousa e Melo et al., 2017; Vanharanta and Massagué, 2013; Wicha
et al., 2006). Thus, an important question is which markers should
be used for CSC and MetSC characterization.
In colorectal cancer (CRC), MetSCs are already present in the
primary tumor (de Sousa e Melo et al., 2017; Varela-Calviño and
Cordero, 2015). Candidate markers for CRC MetSC characterization
include CD166, CD29, CD24, LGR5, EpCAM (CD326), ALDH1,
CDCP1, CXCR4, CC188 (Hsu et al., 2013; Pitule et al., 2014) and
ephrin type B receptor 2 (EphB2) (Rowehl et al., 2014), although
many of these markers are also expressed in normal colonic stem cells
(i.e. LGR5, ALDH1, or CD29), complicating the distinction between
CSCs and normal stem cells. From present knowledge, CRCMetSCs
can be found among the cell population with a high expression ofWnt
targets LGR5+ and EphB2+ (de Sousa e Melo et al., 2017; Jung et al.,
2011; Kemper et al., 2012) co-expressing EpCAM, CD133, CXCR4
and CD26 markers. EpCAM, CD133 and CXCR4 are enriched in a
metastatic cell population with an auto fluorescent subcellular
compartment (Miranda-Lorenzo et al., 2014), and a CD26+/
CD133+/CD44+ CSC population was capable of metastasizing
when transplanted in mice (Pang et al., 2010). Most of these
markers are co-expressed in the primary tumor; so, it is expected that a
particular marker combination may be used to identify MetSCs in
CRC. Intriguingly, a CD26+ circulating tumor cell (CTC) population
that is CD44+ and CD66c+ but EpCAM− and CD133− is an
independent prognostic factor for CRC recurrence (Lieto et al., 2015).
As the number of cells presenting CSC features that can be
obtained from surgical samples is scarce (Oskarsson et al., 2014; de
Sousa e Melo et al., 2017; Varela-Calviño and Cordero, 2015;
James et al., 2015) and CTCs from liquid biopsies are highly
heterogeneous (Khoja et al., 2015; Acosta et al., 2016), several
studies have previously explored the possibility of using established
cell lines. In spite of their inherent genetic instability during long-
term passaging, CTCs are a valid option (Rowehl et al., 2014; Dotse
and Bian, 2016), as they are able to sustain different cell subsetsReceived 9 January 2019; Accepted 24 June 2019
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with CSC features (Zimmerer et al., 2013) and with the inherent
heterogeneity observed in cancer populations (Driessens et al.,
2012; Pitule et al., 2014; Lieto et al., 2015; Zimmerer et al., 2013).
The aim of this study was to test candidate CSC andMetSCmarkers
in a panel of eight cell lines obtained from primary or metastatic
tumors of patients in different disease stages [so that epithelial-
mesenchymal transition (EMT)markers were also used]. The results
would provide a functional characterization of specific cell subsets
found in clinical specimens (Lieto et al., 2015; Cheung et al., 2017)
and the possibility of using these chemo-resistant cells as targets for
the development of new therapies.
RESULTS
Expression of stem cell, CSC and EMT markers in CRC cell
lines
The stem cell, CSC and EMT marker expression profile in eight
CRC cell lines was analyzed by flow cytometry (Table 1), western
blotting (Fig. 1A) and immunofluorescence (Fig. 1B–D). Cytometry
results (Table 1) showed that cell lines SW1116, SW480 and SW620
presented the lowest E-cadherin expression. In western blotting
(Fig. 1A), the mature form of E-cadherin (120 kDa) was detectable
in DLD-1, HT-29, Caco-2, COLO205 and T84 but not in SW1116,
SW480 and SW620, supporting the flow cytometry results. An E-
cadherin high MW band (130 kDa), possibly corresponding to the
inactive precursor (Khoja et al., 2015), was detected in all tested cell
lines, although the expression was very low in SW480 and SW620.
On the contrary, vimentin was only expressed in SW480 and SW620
(Fig. 1A), as expected for a mesenchymal stage and according to the
expression observed for E-cadherin.
A very high frequency of EpCAM+ cells was found in all cell
lines (Table 1) and a band of 40 kDa was observed upon western
blotting for all cell lines (Fig. 1A), suggesting that these cell lines
were fully differentiated carcinoma cells. On the contrary, all cell
lines showed a percentage of stem cells from intestinal origin as
indicated by LGR5 expression, with the highest frequency in T84
cells (22.5%).
Cell lines with the lowest E-cadherin-expression showed low
frequencies of CD44 (SW1116 and SW620), CD26 (SW480 and
SW620), LGR5 (SW620), and CD133 (SW1116 and SW480)
(Table 1) by flow cytometry. However, the expression of these CSC
markers was very heterogeneous in the other cell lines, CD133 and
CD44 being the most variable (between 1% in T84 and 82.9% in
Caco-2 and between 10.1% in COLO205 and 85.9% in Caco-2,
respectively). In the case of CD26, all the cell lines showed a high
expression, except SW480, SW620 and DLD-1 (intermediate
frequency of positive cells). In DLD-1 and COLO205, there was a
lack of correlation between western blotting (Fig. 1A) and flow
cytometry data (Table 1 and Fig. S1), which should be further
investigated.
We also analyzed the autofluorescence phenotype of cell lines
(exclusive of epithelial CSC), which could be enhanced using
riboflavin (Miranda-Lorenzo et al., 2014). All the analyzed cell
lines had a very small subpopulation of CSCs (Table S2).
Immunofluorescence (Fig. 1B–D) showed that the E-cadherin
and EpCAM staining distributions were very similar and
corresponded to those of proteins related to cell–cell interaction.
The distributions of CD44, CD26 and LGR5 staining were more
diffused, although they were plasma membrane proteins. However,
CD26 staining showed a trend for polarization that LGR5 lacked.
Phenotypic characterization of subsets in the cell lines
Current knowledge of normal and tumor tissues indicates that CSCs
are rarely defined by a single marker but by a combination of
multiple molecular markers. On the other hand, several studies have
linked high surface expression of some of these markers with the
tumor degree of differentiation, depth of invasion, clinical stage and
metastatic status in CRC (Acosta et al., 2016; Dotse and Bian, 2016;
Ren et al., 2013; LaBarge and Bissell, 2008; Kojima et al., 2008;
Horst et al., 2008). Therefore, we established all possible
combinations between the markers and all possible combinations
of subpopulations with high intensity expression of markers.
For double positive subsets (Table S3), we observed high
frequencies of almost all the markers in HT-29 and Caco-2 and very
low frequencies in SW480 and SW620, as expected. The other cell
lines showed different expressions depending on the analyzed
subset. We observed that almost all LGR5+ cells in the cell lines
were EpCAM+ (Tables 1 and S3) and had higher frequency of
CD26+/E-cadherin+ cells than of CD133+/E-cadherin+ cells.
Markers with high expression in the cell lines were also observed.
Fig. S2 shows dot plots for LGR5 versus EpCAM and CD133
versus CD26 in COLO205 and Caco cell lines, as examples of the
gating strategy. Cells with high expression of EpCAM were easily
detected in COLO205 and Caco cell lines, and all the cell lines had
EpCAMhigh/LGR5+ subsets (from 2.8% in SW620 to 11.9% in
Caco-2, Table 2), although not all LGR5+ cells were EpCAMhigh. In
the case of dot plots for CD133 versus CD26 (not studied in this
context before) (Fig. S2B, Table 3), one cell line (Caco-2) showed
large CD133+CD26high and CD133high/CD26high subsets (65.3%
and 9.6%, Fig. S2B). Very small CD133/CD26 subsets with high
expression of one or both markers were observed in seven out of the
eight analyzed cell lines (Table 3). In addition, the cell lines had
CD133−/CD26high subpopulations, except the mesenchymal cell
lines (Table S4).
We also looked at possible E-cadherinhigh subsets. Most cell lines
(SW1116, DLD-1, HT-29, Caco-2, COLO205 and T84) harbored
CD26high/E-cadherinhigh, CD26high/E-cadherin+, or E-cadherinhigh/
CD26+ subsets (Table S5), but SW480 and SW620 did not
show any of these subsets. CD133high associated to E-cadherinhigh
Table 1. Frequencies of CD26, CD133, CD44, EpCAM, LGR5 and E-cadherin in colon cancer cell lines
Cell line CD26+(%) M±s.d. CD133+ (%) M±s.d. CD44+ (%) M±s.d. EpCAM+ (%) M±s.d. LGR5+ (%) M±s.d. E-cadherin+ (%) M±s.d.
SW1116 81.1±10.1 7.7±1.2 23.4±4.0 91.4±5.8 10.2±1 43.0±4.5
SW480 2.7±0.8 3.4±2.1 37.0±1.0 91.8±8.8 8.0±1.8 43.4±16.8
DLD-1 41.9±9.1 16.7±3.4 58.3±12.0 85.2±15.2 12.8±2.7 82.6±11.3
SW620 2.3±0.6 60.3±22.8 6.1±1.8 90.0±11.2 3.7±1.3 30.8±6.0
HT-29 75.1±6.8 73.9±6.6 78.1±13.4 97.6±2.7 9.1±4.1 83.9±8.7
Caco-2 86.8±12.1 82.9±10.7 85.9±9.8 91.1±8.3 15.9±6.4 83.2±14.2
COLO205 76.0±9.9 81.8±7.6 10.1±0.3 99.1±1.7 9.9±1.3 90.4±11.4
T84 80.7±4.8 1.0±0.1 25.3±19.0 87.1±1.9 22.5±4.4 76.6±14.6
M: Mean of three experiments.
s.d.: Standard deviation.
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was practically non-existent, and CD133 staining was poor in
E-cadherin+ cells (Table 1 and Table S6).
No subset with high expression of CD44 was observed (data not
shown), but the cells from the CD133high/CD26high subset in the
Caco-2 cell line were CD44− and E-cadherinlow.
Sphere formation in the CRC cell lines under investigation
Whether the cell lines which originated from both primary and
metastatic tumors were able to form spheres was examined. All cell
lines formed spheres in the first generation after 7 days of culture
(Fig. S3), suggesting the presence of CSCs in all cell lines. However,
there were appreciable differences in the structure and size of the
spheres (Fig. S3 and Table S7). SW480, SW620 and COLO205
spheres showed similar morphology andwere different from the other
cell line spheres. Those three cell lines had a low expression of
E-cadherin (120 kDa) (Fig. 1B) as well as a low frequency of CD44
(Table 1). A lack or low expression of E-cadherin and CD44 could
lead to decreased cell-to-cell contacts and to the observed
morphology. However, SW1116 cell line also showed similar
marker expression.
The sphere cells were disaggregated, and cells reseeded to
establish self-renewal capacity by formation of secondary spheres
(Table S7). Only SW1116 did not form secondary spheres. All the
other cell lines did form spheres in three serial passages: DLD-1
formed more spheres and T84 less spheres (data not shown).
Efficiency for self-renewal was essentially maintained through
passages in all cell lines, T84 cells being the most efficient and
SW620 the least efficient (Table S7).
Expression of stem cell, CSC and EMT markers in cells
derived from spheres
The spheres developed in 7-day cultures were disaggregated, and
stem cell, CSC and EMT markers were analyzed by flow cytometry
in sphere-derived cells (sph) (Table 4).
Sphere-derived cells from all cell lines showed high frequencies
of E-cadherin expression, except SW620 (Table 4). As expected for
proliferating cells in epithelial state, E-cadherin frequencies were
much higher in SW1116sph and SW480sph than those in their
respective cell lines (Table 1). However, this was not the case in
SW620sph and T84sph, where the frequencies of E-cadherin
+ were
similar to the original cell line (being a minority in SW620).
More than half of SW1116sph (62%) was LGR5
+, with
approximately 20% of positivity for this marker in the rest of cell
linessph, except SW620sph, where only a minor subset (2.8%) was
Fig. 1. Expression of different markers in the eight human colon cancer cell lines analyzed. (A) Western blot analysis of EpCAM, LGR5, CD26,
E-cadherin and vimentin expression in total cell extracts from the eight cell lines (20 μg of protein in each line). Data shown are representative of three
experiments. (B) E-cadherin and EpCAM expression analysis by immunofluorescence in HT-29 and Caco-2 cells. (C) CD44 and CD26 expression analysis
by immunofluorescence in HT-29 and Caco-2 cells. (D) LGR5 expression analysis by immunofluorescence in DLD-1 and Caco-2 cells. Nuclei were stained
with DAPI. Scale bars: 50 μm.
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LGR5+ (Table 4). Sphere-derived cells showed enhanced
frequencies (two- to three-fold) of LGR5 positivity compared to
the original cell lines (Tables 4 and 1). All the cell linessph showed
high frequencies of EpCAM+ (Table 4). SW1116sph, with high
frequencies of LGR5+, also showed a high frequency (around a
50%) of the LGR5+/EpCAMhigh subset (Table S8, Fig. 2, region B
of dot plots). On the contrary, more EpCAMlow were found in
SW480sph, SW620sph and COLO205sph (SW480sph and SW620sph
showing the lowest frequencies of LGR+). In addition, the large
subset of LGR5+/EpCAMhigh in T84sph showed some LGR5high
cells (Fig. 2, red arrow), which has not been described before.
The frequencies of CD133, CD44 and CD26 in cell linessph
resembled those of the original lines, although there were some
changes: CD133+ frequencies in T84sph were higher than those in
the original cell line (17%), whereas HT-29sph and COLO205sph
showed lower CD133 frequencies than those in the lines of origin
(Fig. S4). CD44 was also found at high frequencies in cell linessph,
except in SW620sph (Table 4). Frequencies were also low in
SW480sph compared to the sphere-derived cells from the other cell
lines. CD26 showed particularly higher frequencies in SW480sph
than those in the original cell line, despite being strikingly similar to
the original cell lines in the other cases (Tables 1 and 4).
Very interestingly, CD133, CD44 and CD26 hardly correlated
(Fig. S4). Intriguingly, although the same cell lines continued to
show a CD26high population in sphere-derived cells, the frequency
was quite a lot lower in Caco-2sph and much higher in T84sph than
those in the original cell lines (Tables S9 and S4). To note, the latter
are the ones with EpCAMhigh/LGR5high. The CD133high/CD26high
subsets were very small in cell linessph but more detectable than in
the original cell lines (Table S10). However, the subsets of
CD133high/CD26− cells in some cell lines (e.g. SW620sph with
4.2%) or in the other combinations (Table S10) showed higher
frequencies than those in the original cell lines.
Relationship between CSC and EMT markers in cells derived
from spheres
All cell linessph showed some E-cadherin
− cells and E-cadherin+
subsets corresponding to mesenchymal and epithelial cells,
respectively. The subsets of E-cadherin− cells in all cell linessph
had a higher percentage of small size cells than that of the subsets of
E-cadherin+ cells (e.g. DLD-1sph in Fig. 5). We analyzed if CSC
markers were differentially expressed in both E-cadherin− and
E-cadherin+ sphere-derived cells.
Markers in E-cadherin− sphere-derived cells
Most but not all E-cadherin− cells are also CD133−, CD26−, or
CD44− (e.g. CD133 in Fig. 5). A common characteristic in these
E-cadherin− cells was the presence of one or more subsets expressing
only one marker in different combinations in all cell linessph, and co-
expression of CD133/CD26 was not found in five of them.
SW1116sph was CD133+, CD26+ and CD44+, and had a few
CD26+/CD44+ cells (2.3%); SW480sph and SW620sph were totally
CD26−, with a high percentage of CD133+ and a low percentage of
CD44+ or CD133+/CD44+; DLD-1sph had small subsets of only
CD26+, CD44+ and CD133+ cells; HT-29sph had a small subset of
CD133+/CD26+/CD44+, CD44+/CD26+, or only CD44+ cells; Caco-
2sph had a large CD133+/CD26+/CD44+ and CD26+/CD44+ subsets
and a small CD26+ or CD44+ subset; COLO205sph had a large
CD26+ subset and a small CD133+/CD26+ subset; T84sph wasmostly
CD133−, with a high CD26+ percentage and a low percentage of
CD44+ or CD26+/CD44+.
Markers in E-cadherin+ sphere-derived cells
Although still having small cells, the majority of the cells in the
E cadherin+ subset were large, and almost all large cells were in
this subset (Fig. S5). The frequency of the CD26+/CD44+ subset
increased independently of the expression of CD133, although there
were still cells only CD26+ or CD44+ (data similar to Fig. S4).
Moreover, this CD26+/CD44+ subset correlated with the stage of
origin of the cell line (larger subsets in cell lines from advanced stage
tumors, data not shown), irrespective of the presence of CD133.
A correlation between E-cadherin and CD26 was observed in
most cell linessph. A population of E-cadherin
high cells was observed
in all cell linessph (Fig. S6, regions A and B), except in SW620sph,
and these cells were mainly CD26high (Fig. S6, region B, and
Table S11). A similar profile was found many times for CD44 (data
not shown). However, in the case of CD133, although some
E-cadherinhigh cells showed CD133 staining (Table S6), most
CD133+ cells were E-cadherin− (Table 4 and Table S3).
Interestingly, positivity for E-cadherin and LGR5 and their
fluorescence intensity were strongly correlated (Fig. 3), and no
LGR5+ cells were E-cadherin−. These cells were also more complex
in morphology (SSC axes in Fig. 3B). As shown in Fig. 3B (region 6
in the UR quadrant) and from other results not shown, we confirmed
that when CD26high cells were present, they were LGR5+. However,
there were some LGR5+ cells without CD26 and CD133 markers
(e.g. Caco-2sph in Fig. 3C).
Therefore, as LGR5 and E-cadherin expression correlate in
sphere cells (Fig. 3A) – as well as LGR5 with EpCAM (Fig. 2) and
with CD26 (Fig. 3B), and also E-cadherin with CD26 (Fig. S6) but
not with CD133 (Fig. 3C) – it can be deduced that, in sphere derived
cells from lines of advanced tumor stage, the E-cadherin+/LGR5+/
EpCAMhigh cells are also CD26high. Some of these E-cadherin+/
Table 2. Frequencies of EpCAMhigh/LGR5+and EpCAMlow/LGR5+
subsets in colon cancer cell lines









M: Mean of three experiments.
s.d.: Standard deviation.










SW1116 0.08±0.15 3.05±2.15 0.03±0.04
SW480 - - -
DLD-1 - 0.03±0.05 0.05±0.10
SW620 - - 0.40±0.55
HT-29 0.30±0.18 1.13±0.21 0.20±0.08
Caco-2 9.58±11.34 12.13±11.98 0.38±0.22
COLO205 - 0.05±0.06 0.15±0.10
T84 - 1.33±1.03 -
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LGR5+/EpCAMhigh /CD26high., but not all, were CD133+ or
CD133high (Fig. 3C), and most were CD44+ (Fig. S4).
Clustering of markers in sphere-derived cells
To confirm the above finding, LGR5+/EpCAMhigh subsets from
T84sph were sorted into E-cadherinlow and E-cadherinhigh subsets,
which were analyzed for CD26, CD44 and CD133 expression
(Fig. 4). Both subsets showed low expression of CD133 and CD44.
The E-cadherinhigh subset was mostly CD26+ (82%), while the
E-cadherinlow subset was only 20% CD26+.
DISCUSSION
We show for the first time that LGR5+, E-cadherinhigh, EpCAMhigh
and CD26high are frequently associated in sphere-derived cells, that
CD133 seems to be related to a different germinal line, and that cell
division affects the expression of all markers, including that of
E-cadherin. These results are highlighted with the recent report that
has shown that LGR5+ cells are more important for the process of
metastasis than for primary tumor growth (de Sousa e Melo et al.,
2017).
Circulating human CD133+/CD26+/CD44+ cells but not
CD133+/CD26−/CD44+ cells have been detected in the portal
vein of mice at week 6 after cecal wall injection, demonstrating the
invasion of CD26+ cells into the circulation of orthotopically
implanted mice, leading to the development of liver metastasis
(Pang et al., 2010). Interestingly, E-cadherin expression was down-
regulated in CD133+/CD26+ cells from primary CRC tumors
compared to CD133+/CD26− cells, with the concomitant
upregulation of N-cadherin, the E-cadherin repressor slug, as well
as other EMTmarkers, such as twist, fibronectin and vimentin (Pang
et al., 2010; Cheung et al., 2017). Here, we show that, in most
analyzed cell lines, CD133 and CD26 are hardly expressed together
and CD133−/CD26+ sphere cells (perhaps CSCs) are a major
population. Although the subset E-cadherinlow or−/CD133+/CD26+
could be found in all lines and also in sphere-derived cells, the
E-cadherinhigh/CD133−/CD26+ subset was particularly large in cell
Table 4. Frequencies of CD26, CD133, CD44, EpCAM, LGR5 and E-cadherin in cells disaggregated from spheres grown from colon cancer cell lines
Cell linesph CD26+ % M±s.d. CD133+ % M±s.d. CD44+ % M±s.d. EpCAM+ % M±s.d. LGR5+ % M±s.d. E-cadherin+ % M±s.d.
SW1116 84.6±12.9 30.2±19.7 52.2±12.9 84.4±8.7 62.1±12.3 84.4±6.3
SW480 22.1±10.3 31.3±26.7 35.6±20.2 82.7±12.6 22.3±3.3 73.8±12.1
DLD-1 47.7±28.2 24.5±9.3 77.5±6.9 84.8±11.2 26.1±21.3 86.5±8.8
SW620 1.8±0.7 62.6±14.5 6.1±5.7 91.6±7.6 2.8±2.7 35.4±26.1
HT-29 92.4±8.6 54.2±11.5 77.6±12 93.6±4.9 22.3±27.9 84.5±13.5
Caco-2 98.0±2.9 77.8±4.8 96.8±2.9 97.5±3 16.9±19 90.0±8.8
COLO205 85.7±1.1 73.0±17.4 85.0±1.7 77.3±18.1 19.5±11.9 86.8±14.1
T84 73.6±8.3 17.6±6.7 70.7±6.5 79.0±11.5 29.0±7.6 79.1±16.4
Cell linesph: Spheres derived-cells for each cell line.
M: Mean of three experiments.
s.d.: Standard deviation.
Fig. 2. Flow cytometry analysis of LGR5/EpCAM in sphere-derived cells. T84sph showed a subset with LGR5 high expression (LGR5high, red arrow).
LGR5+/EpCAMlow region A, LGR5+/EpCAMhigh region B.
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lines from advanced CRC stages. This result is consistent with the
fact that in humans, the population isolated from the primary tumor
comprising CD133+/CD44+/CD26+ cells (and E-cadherinlow or
E-cadherin−) is not the only CSC population present in the tumor
biopsies (Pang et al., 2010).
Several studies linked CD133high expression with a high risk of
metastasis in CRC patients (LaBarge and Bissell, 2008; Kojima et al.,
2008; Horst et al., 2008; Ong et al., 2010; Gallmeier et al., 2011), but
the effective value of CD133 as a CSC biomarker is unclear, because,
as observed in the SW620 colon cell line, sorted CD133+ and
CD133− subsets can undergo conversion between the two subsets
(Hsu et al., 2013; LaBarge and Bissell, 2008; Kojima et al., 2008).
E-cadherin was used as a control of EMT. CSCs exist both in
epithelial and mesenchymal states (Liu et al., 2014a,b), but EMT
favors migration of cancer cells while inhibiting cell proliferation.
Thus, MetSCs should be found in the epithelial state in the primary
tumor, in the mesenchymal state in the peripheral blood (Oskarsson
et al., 2014; Zimmerer et al., 2013), and in the epithelial state in the
host organ. We assume that the loss of E-cadherin expression in
sphere-derived cells (spheres were obtained over a 7-day period) is
because they are newborn proliferating cells (that is, epithelial cells
but lacking E-cadherin), rather than mesenchymal cells. However,
the discrimination between sphere-derived small cells losing
E-cadherin expression and mesenchymal cells proliferating should
be a priority of further research because these small cells, which
completely lost EpCAM and LGR5 expression (recovered as they
enlarged), were found in every passage of sphere-derived cell
cultures, thus, data of LGR5 positivity could underestimate the
frequency of intestinal CSCs in this work and in vivo. Interestingly,
CD133, CD26 and CD44 expression remained in some of these small
cells. The positivity for one or more of these markers was useful to
identify each cell line, suggesting the presence of different lineages
(e.g. E-cadherin−/CD133+ was the origin of the CD133high subsets in
the cell lines). In a very important study that described the stemness of
spheroid-derived stem-like colon cancer cells from lines, the cells
used in this work, these markers were not tested (Han et al., 2013).
EpCAM (CD326) overexpression is an early event during cancer
progression in some types of tumors such as prostate and lung
cancer, as well as in CRC (Miranda-Lorenzo et al., 2014; Pitule
et al., 2014; Rowehl et al., 2014; Liu et al., 2014a,b). EpCAM
appears in 85% of colorectal carcinomas, it can inhibit
differentiation and promote proliferation (Hsu et al., 2013), and it
is used to isolate CTCs in liquid biopsies (Dotse and Bian, 2016).
Although the presence of EpCAMhigh/CD44+ cells correlated
with the degree of differentiation, depth of invasion, clinical stage
andmetastatic status in CRC (Liu et al., 2014a,b) and gastric cancers
Fig. 3. Flow cytometry analysis of LGR5/E-cadherin, LGR5/CD26 and CD26/CD133 in sphere-derived cells. (A) Two representative dot plots of LGR5
versus E-cadherin expression in COLO205sph and HT-29sph. (B) LGR5 versus CD26 expression in T84sph. CD26high/LGR5+cells are marked in R6 region in
UR quadrant. Physical gatings (FCS versus SSC) of the four quadrants of T84sph are shown. (C) Caco-2sph representative dot plots for CD26 versus CD133
and, on the right, LGR5 versus E-cadherin dot plots of the four regions gated on the left CD26/CD133 dot plot.
6









 by guest on April 23, 2020http://bio.biologists.org/Downloaded from 
(Han et al., 2011), because of the plasticity and the not completely
known role of their isoforms, CD44 expression does not seem to be
an appropriate marker of MetSCs (Hsu et al., 2013; Pitule et al.,
2014; Rowehl et al., 2014; Qiu et al., 2015; Nagano and Saya,
2004). However, in E-cadherin expressing cells, we observed that
the frequency of the CD26+/CD44+ subset increased independently
of the expression of CD133.
LGR5 is a well-characterized marker of intestinal and colon stem
cells (de Sousa e Melo et al., 2017; Kemper et al., 2012; Osawa
et al., 2016; Zhang et al., 2016; Basu et al., 2016). We observed that
sphere-derived cells showed a high frequency of the LGR5+/
EpCAMhigh subset in many cell lines. This subset can represent
clonogenic CSCs that proliferate originating the sphere (de Sousa e
Melo et al., 2017; Zimmerer et al., 2013). However, in some cell
lines, the frequency of LGR5+/EpCAMlow cells was high and there
were very low frequencies of EpCAMhigh found in SW480sph,
SW620sph and COLO205sph. Interestingly, a small LGR5
+/
EpCAM− subset was detected in all linessph, probably
representing the CD26+/CD44+/CD66c+ but EpCAM(CD326)−
and CD133− CTC population that was an independent prognostic
factor for CRC recurrence (Lieto et al., 2015).
Based on the fact that there are immune helper T cells with a
defined CD26high phenotype (Krakauer et al., 2006), we tested if a
similar subset with high staining of CD26 was present in CRC cell
lines. Our data showed that the EpCAMhigh/LGR5+ subset had high
expression of E-cadherin and CD26, with variable frequency among
the cell lines. The subset was mostly CD44+, and CD133+ or
CD133−, but there were also cells only CD26+. The frequency of
this E-cadherin+/LGR5+/EpCAMhigh/CD26high lineage resembled
that of the auto-fluorescent CSCs (Miranda-Lorenzo et al., 2014).
In addition, cell lines had cells only CD133+, particularly cell
lines from early stages. The CD133high/CD26high and CD133high/
CD26+ subsets present in the cell lines (both CD44− and
E-cadherinlow, unlike the CD133+/CD26high subset) were not
found in sphere-derived cells, suggesting additional clonogenic
subsets that might be less related to the metastatic process (de Sousa
e Melo et al., 2017).
In a previous study where the effect of chemotherapeutic
adjuvants 5-fluorouracil, vinblastine, oxaliplatin, methotrexate, or
irinotecan was studied on cell lines and in orthotropic tumor cells
(Cutler et al., 2015), chemotherapy agents led to the loss of
CXCR4+, another candidate marker in epithelial cancer cells
(Miranda-Lorenzo et al., 2014; Jung et al., 2011; Rowehl et al.,
2014; Cutler et al., 2015; Liao et al., 2010; Davies et al., 2015), in
combination with CD133+ (CXCR4+/CD133+), and to the
enrichment of CD26+/CD44+ cells, in agreement with our results,
although our data show that these chemotherapy agents are not
necessary to enhance CD26 and CD44 expression, as Cutler et al.
suggest (Cutler et al., 2015). All in all, these data are supporting the
role of CD26 in MetSCs (Cheung et al., 2017; Liao et al., 2010;
Davies et al., 2015; Lam et al., 2014; Nishikawa et al., 2015; Collura
et al., 2013; Gemei et al., 2013; Grunt et al., 2015) and the presence
of at least two lineages of CSCs (Basu et al., 2016).
CD26 is related to some extent to the CXCR4/SDF-1 axis,
because SDF-1 (CXCL-12) is a substrate of CD26/DPP4 enzymatic
activity. However, most of the markers studied, including CD26, are
related to cell–cell adhesion directly (as E-cadherin or EpCAM) or
indirectly through the ECM. CD26 is known to associatewith ADA,
fibronectin and collagen (Cheng et al., 2003; Ghersi et al., 2002;
Naim et al., 1999), and its binding to proteoglycans versican and
Fig. 4. Sorting strategy of T84sph. T84sph LGR5+ (top histogram) and EpCAMhigh (middle histogram) were sorted into E-cadherinlow and E-cadherinhigh
subsets (bottom histogram). E-cadherinlow and E-cadherinhigh subsets (on the right) were analyzed for CD26, CD133 and CD44 expression.
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glypican-3 has been suggested (Havre et al., 2013; Khurana et al.,
2013). CD44 is a receptor for hyaluronic acid (Liu et al., 2014a,b;
Han et al., 2011). Nevertheless, whereas CD44 has functions only in
cell adhesion and signaling, CD26 also has DPP4 activity in the
intestinal brush border of normal mucosa with a role in protein
digestion (Naim et al., 1999). To note, most primary tumors lose
CD26 expression, and this may explain the difference between
CD44 and CD26 staining of cell lines, although both can be cleaved
from the cell surface (Nagano and Saya, 2004; Cordero et al., 2009).
In fact, we demonstrated recently that soluble CD26 levels (sCD26)
were a much better serum marker for the detection of CRC
metastasis or tumor recurrence compared to other markers in clinical
use, such as CEA, CA-19.9, or CA-72.4 (De Chiara et al., 2014). At
the same time, a relationship between the presence of CD26+ cells,
detected by immunohistochemistry in primary CRC tumor biopsies,
and the prognosis of metastasis has been demonstrated (Grunt et al.,
2015), as well as between the presence of CD26+/CD44+ and
EpCAM−/CD133− CTC population, detected in liquid biopsy,
and the prognosis of colorectal cancer recurrence (Lieto et al.,
2015). It remains to be elucidated if these cells or the LGR5high/E-
cadherinhigh/EpCAMhigh/CD26high cells described here cause
metastasis in mice as the CD26+/CD133+/E-cadherinlow CSC
population (Pang et al., 2010).
CD26 and/or dipeptidyl peptidase 4 inhibitors can prevent colon
cancer and lung metastasis in animal models (Angevin et al., 2017;
Jang et al., 2015; Femia et al., 2013; Yorifuji et al., 2016), although
epidemiological studies in humans are not clear (Enz et al., 2019).
There are also encouraging results regarding anti-CD26 Ab in
mesothelioma, renal and urological tumors (Enz et al., 2019).
Overall, studies investigating CD26+ subsets may ultimately
contribute to the development of new treatment options for CRC
(Cheung et al., 2017; LaBarge and Bissell, 2008; Han et al., 2013,
2011; Qiu et al., 2015; Osawa et al., 2016; Cutler et al., 2015;
Khurana et al., 2013).
MATERIALS AND METHODS
Cell lines and culture conditions
Eight human colon cancer cell lines, SW1116, SW480, DLD-1,
SW620, HT-29, Caco-2, COLO205 and T84 were obtained from the
American Type Culture Collection (ATCC). SW1116, SW480,
DLD-1, SW620, HT-29 and Caco-2 were cultured in DMEMmedia
(Lonza) supplemented with 10% fetal bovine serum (FBS) (Sigma-
Aldrich), 1% L-glutamine (Sigma-Aldrich) and 1% penicillin/
streptomycin (Sigma-Aldrich). COLO205 was maintained in RPMI
1640 media (Lonza) supplemented with 10% fetal bovine serum
(FBS), 1% L-glutamine and 1% penicillin/streptomycin. T84 was
maintained in DMEM/Ham’s F12 media (Lonza) supplemented
with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin.
Cells were grown at 37°C in a humidified atmosphere of 5% CO2.
Dukes’ stage and tissue origin for each cell line is shown in
Table S1.
Sphere formation assay
Sphere formation media was composed of serum-free DMEM/F12
(1:1), 20 ng/ml epidermal grow factor (EGF; Calbiochem), 10 ng/
ml basic fibroblast growth factor (bFGF; Calbiochem), 5 µg/ml
insulin (Sigma-Aldrich), 1x B-27® Supplement without Vitamin
A (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich). For
sphere suspension culture, cell lines grown in a two-dimensional
monolayer were digested with trypsin (Lonza) and seeded at a
density of 1×104 cells/ml in serum-free medium (SFM), in
100 mm ultra-low attachment plates (Corning) at 37°C and in a
humidified atmosphere of 5% CO2. The number and diameter of
spheres were evaluated after 7 days. Medium was supplemented
every alternate day to maintain proliferation and viability in all
plates.
For serial passages, 7-day-old spheres were harvested and
dissociated into single cells with trypsin. Dissociated cells were
replaced in a new plate and cultured for 7 days. Efficiency of self-
renewal was calculated from the number of cells formed in each
passage from one single cell reseeded (100 cells/well).
Antibodies
Antibodies used for western blot, immunofluorescence and flow
cytometry were as follows: anti-CD26 (≠AF1180, R&D Systems),
anti-CD26 (≠H00001803-D1 Novus Biologicals), anti-E-cadherin
(≠610181, BDBiosciences), anti-vimentin (≠MA5-11883, Thermo
Fisher Scientific Pierce), anti-EpCAM (≠2929, Cell Signaling
Technology), anti-LGR5 (≠TA503316, OriGene Technologies),
anti-CD133 (≠MAB4399, Millipore), anti-CD44-FITC (≠44F2,
Immunostep), anti-CD133-APC (≠AC133 Miltenyi Biotech), anti-
EpCAM-FITC (≠130-098-113, Miltenyi Biotech), anti-LGR5-PE
(≠1030-100848, Miltenyi Biotech), anti-CD26-PE (≠26PE,
Immunostep), anti-CD26-FITC (≠26F, Immunostep) and anti-E-
cadherin-PerCP-Cy5.5 (≠563573, BD Biosciences).
Secondary antibodies used for western blot were horseradish
peroxide (HRP)-conjugated antibodies (Sigma-Aldrich). Secondary
antibodies used for immunofluorescence were goat anti-rabbit
AlexaFluor®488 and goat anti-mouse AlexaFluor®594 (Thermo
Fisher Scientific).
Western blot analysis
Cells were lysed in RIPA buffer (50 mMTris-HCl, pH 7.5; 150 mM
NaCl; 1% NP-40; 0.5% sodium deoxycholate and 0.1% SDS),
supplemented with protease inhibitor cocktail (Roche). Insoluble
components were removed by centrifugation and protein
concentrations were measured using the Bradford protein assay
(Bio-Rad). Equal amounts of protein (20 µg) were separated by
SDS-PAGE and transferred onto PVDF membranes (Immobilon-P,
Millipore). Membranes were blocked with 5% non-fat dry milk in
PBST (0.1% Tween-20) for 1 h and probed with the primary
antibodies diluted in PBST/5% non-fat dry milk. After washing,
membranes were incubated with secondary horseradish peroxide-
conjugated antibodies. Protein signals were visualized with the
Clarity Western ECL Substrate (Bio-Rad) according to the
manufacturer’s protocol. Images were acquired using a ChemiDoc
XRS+ system (Bio-Rad). Quantitative image analysis was
performed with Image lab software (Bio-Rad). Full-length blots
of expression of different markers in the eight human colon cancer
cell lines analyzed are showed in Fig S7.
Immunofluorescence
Culture cells were grown in appropriate medium on glass coverslips
until 70–80% confluence. Cells were fixed with 4%
paraformaldehyde for 30 min at 37°C followed by permeabilization
with 0.5%TritonX-100-phosphate buffered saline (PBS) for 3 min at
room temperature. Cells were blockedwith 2%bovine serum albumin
in PBS for 30 min. Then cells were incubated with the appropriate
primary antibodies for 1 h. After several washes, cells were incubated
with appropriate fluorescent secondary antibodies for 45 min in the
dark. Cell nuclei were stained with DAPI (1 µg/ml). The coverslips
were mounted with MOWIOL on microscope slides and
immunofluorescence was visualized using a fluorescence
microscope (Olympus-BX51).
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Flow cytometry and cell sorting analysis
Human colon cancer cells derived from monolayer cultures and
sphere-derived cells on day 7 after primary culture were adjusted to
a final concentration of 106 cells/ml. Cell suspensions were
incubated for 10 min with blocking solution and with appropriate
antibodies in the dark at 4°C for 30 min. Cells were then washed
with PBS and analyzed by flow cytometry (BD Accuri™ C6, BD
Biosciences). We repeated each characterization three times to
validate the results observed. We followed the protocol of Miranda-
Lorenzo et al. (2014) to acquire autofluorescent cells from cultured
cells: 30 µM riboflavin (Sigma-Aldrich) was added to cultured cells.
For FACS acquisition cells were incubated overnight at 37°C,
centrifuged at 300 g for 5 min and cell pellets re-suspended in PBS.
Autofluorescent cells were excited with 488–561 nm laser and
selected as the intersection with filters 496/578. Propidium iodide
(Sigma-Aldrich) was used for exclusion of dead cells. Cell sorting
was performed in a FACSAria IIu analyzer (BD Biosciences) by
using the PC FACSDiva software program (BD Biosciences).
Gating strategies
Cells were gated on physical parameters (forward-scatter versus
side scatter) to exclude dead or apoptotic cells, cell debris and
aggregated cells. Single cells were gated on FSC-Area versus FSC-
Height profile for excluding doublets.
An autofluorescence analysis was done with unstained cells and
the background level was also determined for each fluorochrome.
This helped us to evaluate the spillover of the different fluorochromes.
Compensation controls were included for each fluorochrome.
Isotype controls were used to mark positive or negative staining.
These marks were properly changed when any subset with high
expressions (over the usual expression) of some CSC markers were
observed in the different populations studied.
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